SAN FRANCISCO, Feb. 6, 2017 /PRNewswire/ -- Symic Bio, a clinical-stage biotech company that is developing a new category
BIO CEO & Investor Conference
Date: Monday, Feb. 13, 2017
Time: 9:30 a.m. EST
Location: Waldorf Astoria, New York
Cowen and Company Health Care Conference
Date: Monday, March 6, 2017
Time: 3:30 p.m. EST
Location: Boston Marriott Copley Place
About Symic Bio
Symic Bio is a clinical-stage biotech company that is developing a new category of therapeutics that are matrix regulators. Matrix regulators target the non-cellular component of tissue and enable new ways to affect disease and healing processes. Matrix regulators have potential applications in a wide variety of indications. Symic Bio currently has two clinical candidates, SB-030 for the treatment of critical limb ischemia and SB-061 directed at disease modification in the treatment of osteoarthritis. In addition, Symic Bio is investigating applications in the areas of fibrosis, oncology and diseases of the central nervous system.
For additional information please visit the company's website at www.symic.bio, LinkedIn page at www.linkedin.com/company/symic-bio or follow on Twitter at www.twitter.com/symicbio.
Gitanjali Jain OgawaThe Trout Group(646) firstname.lastname@example.org
David Schull or Rich AllanRusso Partners, LLC(212) 845-4271(646) email@example.com firstname.lastname@example.org
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/symic-bio-to-present-at-upcoming-conferences-300402276.html
SOURCE Symic Bio
Subscribe to our Free Newsletters!
Pterygium or Surfer's eye is described as a proliferative disorder of the ocular surface possibly ...
Ecchymosis is a flat, discolored patch of skin that occurs when there is bleeding underneath; it is ...
Age related macular degeneration is a disease of the elderly, wherein the macula or the central ...View All